A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

NCT07548840 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperphosphatemia Patients on Hemodialysis

Interventions

DRUG: TS-172 20~60 mg/day

Sponsor

Taisho Pharmaceutical Co., Ltd.